PDPN and glioma: Furthermore, we adjusted for positive podoplanin expression on tumor samples (CCL3: adjusted HR per double increase: 0.384, 95% CI: 0.146–0.830, p = 0.017) and IDH1 mutation status (CCL3: adjusted HR per double increase: 0.412, 95% CI: 0.174–0.975, p = 0.044), and the inverse association of serum CCL3 levels with risk of glioma-associated VTE prevailed.